Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers

T. E. Keane, Gary Rosner, J. T. Donaldson, D. L. Norwood, S. H. Poulton, P. J. Walther

Research output: Contribution to journalArticle

Abstract

The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

Original languageEnglish (US)
Pages (from-to)1004-1009
Number of pages6
JournalJournal of Urology
Volume144
Issue number4
StatePublished - 1990
Externally publishedYes

Fingerprint

Dipyridamole
Testicular Neoplasms
Heterografts
Urinary Bladder Neoplasms
Cisplatin
Methotrexate
Tumor Burden
Growth
Nude Mice
Neoplasms
Carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Keane, T. E., Rosner, G., Donaldson, J. T., Norwood, D. L., Poulton, S. H., & Walther, P. J. (1990). Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. Journal of Urology, 144(4), 1004-1009.

Dipyramidole-cisplatin potentiation : Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. / Keane, T. E.; Rosner, Gary; Donaldson, J. T.; Norwood, D. L.; Poulton, S. H.; Walther, P. J.

In: Journal of Urology, Vol. 144, No. 4, 1990, p. 1004-1009.

Research output: Contribution to journalArticle

Keane, TE, Rosner, G, Donaldson, JT, Norwood, DL, Poulton, SH & Walther, PJ 1990, 'Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers', Journal of Urology, vol. 144, no. 4, pp. 1004-1009.
Keane, T. E. ; Rosner, Gary ; Donaldson, J. T. ; Norwood, D. L. ; Poulton, S. H. ; Walther, P. J. / Dipyramidole-cisplatin potentiation : Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. In: Journal of Urology. 1990 ; Vol. 144, No. 4. pp. 1004-1009.
@article{3bd6d660cc904993a107bdf19e49e26c,
title = "Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers",
abstract = "The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97{\%}, 65{\%} and 49{\%} of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20{\%} and 17{\%}, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.",
author = "Keane, {T. E.} and Gary Rosner and Donaldson, {J. T.} and Norwood, {D. L.} and Poulton, {S. H.} and Walther, {P. J.}",
year = "1990",
language = "English (US)",
volume = "144",
pages = "1004--1009",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Dipyramidole-cisplatin potentiation

T2 - Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers

AU - Keane, T. E.

AU - Rosner, Gary

AU - Donaldson, J. T.

AU - Norwood, D. L.

AU - Poulton, S. H.

AU - Walther, P. J.

PY - 1990

Y1 - 1990

N2 - The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

AB - The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

UR - http://www.scopus.com/inward/record.url?scp=0025194067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025194067&partnerID=8YFLogxK

M3 - Article

C2 - 2398547

AN - SCOPUS:0025194067

VL - 144

SP - 1004

EP - 1009

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -